Filtered By:
Condition: Antiphospholipid Syndrome
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 523 results found since Jan 2013.
Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin
AbstractAntiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, and/or small vessel thrombosis, pregnancy morbidity, and persistently elevated levels of antiphospholipid antibodies (aPL). Cardiovascular disease (CVD) in APS can present as heart valvular disease (HVD), macro-micro-coronary artery disease (CAD), myocardial dysfunction, cardiac thrombi, or pulmonary hypertension. Brain disease presents as stroke or transient ischemic attack (TIA) and less frequently as cerebral venous thrombosis, seizures, cognitive dysfunction, multiple sclerosis (MS) −like syndrome, or chorea. Infarcts...
Source: Clinical Rheumatology - June 10, 2021 Category: Rheumatology Source Type: research
Antiphospholipid antibodies and cerebrovascular thrombosis in the pediatric population: Few answers to many questions
Lupus. 2021 Jun 4:9612033211021488. doi: 10.1177/09612033211021488. Online ahead of print.ABSTRACTMost of the knowledge in pediatric antiphospholipid syndrome (APS) is derived from studies performed on the adult population. As in adults, antiphospholipid antibodies (aPL) can contribute to thrombosis, especially cerebrovascular thrombosis, in neonates and children. Since aPL have the potential to cross the placental barrier, and since the pediatric population is prone to infections, re-testing for their positivity is essential to specify their role in cerebrovascular thrombosis.In this review, we aimed at assessing the prev...
Source: Lupus - June 4, 2021 Category: Rheumatology Authors: Georges El Hasbani Ali T Taher Nadine Sunji Savino Sciascia Imad Uthman Source Type: research
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
P030 Antiphospholipid syndrome and giant cell arteritis: a coincidence or connection?
Conclusion In summary, this is a case of GCA and APS, treated with prednisolone, aspirin, warfarin and tocilizumab. There is increasing evidence describing the presence of antiphospholipid antibodies in patients with vasculitis. However, the role of these antibodies in GCA and the clinical significance rema ins unclear. This case reports highlights the need for physicians to consider APS in patients who have a history of GCA and subsequently develop arterial or venous embolic events.Disclosure L. Sammut: None.E. Htut: None.
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
JOHN STAPLETON on the 'cure' that killed his wife Lynn Faulds Wood
JOHN STAPLETON: Lynn Faults Wood suffered a stroke caused by a disease of which few people have heard. A disease with the hard-to-remember name of antiphospholipid syndrome
Source: the Mail online | Health - April 20, 2021 Category: Consumer Health News Source Type: news
Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19
We present a 43-year-old female with a history of seropositive-antiphospholipid syndrome and systemic lupus erythematosus who developed an acute ischemic stroke in the setting of mild COVID-19 infection despite adherence to chronic systemic anticoagulation.
Source: Journal of Stroke and Cerebrovascular Diseases - April 12, 2021 Category: Neurology Authors: Keith J. Kincaid, Alexis N. Simpkins Source Type: research
Cardiovascular Considerations in Anesthetic Management for a Patient With Antiphospholipid Syndrome and Decreased Cardiac Function: A Case Study
Anesth Prog. 2020 Mar 1;68(1):33-37. doi: 10.2344/anpr-67-03-07.ABSTRACTThis case report describes the prolonged general anesthetic management of a 41-year-old woman with antiphospholipid syndrome (APS), systemic lupus erythematosus, and previously undiagnosed decreased cardiac function who underwent planned partial resection of the left tongue, tracheostomy, neck dissection, and pedicled flap reconstruction. This was immediately followed by emergent surgery to salvage the flap, and 1 month later, revision of the soft tissue flap was performed. A preoperative echocardiogram was performed because of her various risk factors...
Source: Anesthesia Progress - April 7, 2021 Category: Anesthesiology Authors: Makiko Shibuya Yukifumi Kimura Shigeru Takuma Nobuhito Kamekura Dds Toshiaki Fujisawa Source Type: research
